ASX Health Stocks: Recce Pharma gel could be answer to antibiotic-resistant infections
Recce Pharma lifted more than 20 per cent after announcing its R327G gell had shown promise in combating antibiotic-resistant infections.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Recce Pharma (ASX:RCE) raced higher by more than 20 per cent on Tuesday morning after announcing that its new gel (R327G) had shown it may be a potent weapon against multiple antibiotic-resistant infections.
R327G was being assessed under the TGA Special Access Scheme Category A (SAS – Category A) by a qualified medical practitioner on patients suffering from antibiotic-resistant gram-positive and gram-negative bacterial infections.
For the latest health news, sign up here for free Stockhead daily newsletters
One of the patients in the study, a 70–75-year-old male, had a puncture wound from a metal spike injury.
Unresponsive to all prior antibiotics, the infection had spread until the point where the patient had begun preparing for surgical intervention.
However, 24 hours after using one dose of R327G, the infection had clinically responded (no pre-treatment wound debridement was required).
Furthermore, the redness and swelling of the wound was reduced with no reported stinging at any point. At 30 days post-treatment, the wound had successfully healed and closed.
Another patient to report positive results was a 72-year-old male with type 2 diabetes, who had been unresponsive to all prior antibiotics. His feet had shown significant bacterial infection, redness and swelling.
Seven days after applying R327G, the initial redness and swelling had minimised, with the wound healing and drying. By day 10, he was showing no signs of infection or pus formation and the wound was continuing to heal.
Recce acknowledged that R327 and R327G were experimental compounds, not market approved for use in humans, with safety and efficacy still to be determined by present clinical studies.
“The results shown must be considered anecdotal, and are only presented in the interest of continuous disclosure obligations and are not part of any present clinical trials,” noted Recce.
MORE FROM STOCKHEAD: Firebrick anti-Covid spray passes test | Kava ‘could go global’ | Biotechs down but not out
Emyria launches ketamine program
Emyria (ASX:EMD) announced the launch of its ketamine-assisted therapy (KAT) program, located at the Pax Centre in WA, and with support from newly appointed scientific adviser, Dr Ben Sessa.
Dr Sessa, who has supervised more than 100 KAT sessions, will help develop unique protocols for Emyria that combine ketamine with integrative psychotherapy for a range of mental health conditions.
Recent Australian research suggested the potential of ketamine as a promising treatment for severe and treatment-resistant depression.
Results from these studies showcased that a significant proportion of participants achieved remission or notable reductions in depressive symptoms following a month-long regimen of ketamine injections.
However, the therapeutic benefits seem to wane once treatment was discontinued, indicating the potential need for sustained or periodic treatment to maintain its antidepressant impact.
Emyria’s KAT offering is expected to increase options for patients, and provides them with emerging mental health treatments.
Visit Stockhead, where ASX small caps are big deals
Race Oncology lays out strategy
Meanwhile, Race Oncology (ASX:RAC) has launched its new corporate strategy, detailing the company’s clinical programs and focus on driving lead drug Bisantrene’s commercial potential.
Race says the company is committed to developing the bisantrene formulation RC220, with a clinical focus on investigating its anti-cancer properties.
The secondary focus meanwhile would be on pursuing increased anti-cancer/FTO benefits of Bisantrene, combined with current standard of care therapies in acute myeloid leukaemia (AML).
“Race’s revised development program has been designed in such a way that our new Bisantrene formulation can fit straight into a global pharmaceutical partner’s pipeline,” explained Race CEO, Damian Clarke-Bruce.
“We have a clear regulatory pathway and a program that is supported by international key opinion leaders, for a drug candidate which has already been shown to improve patients’ lives.”
This content first appeared on stockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here
Originally published as ASX Health Stocks: Recce Pharma gel could be answer to antibiotic-resistant infections
Investor Guide: Health & Biotech FY2025
In this special investor guide, health and biotech guru Tim Boreham leads Stockhead’s deep dive into the most cutting edge sector on the ASX.
Investor Guide: Gold & Copper FY2025
Stockhead's writers - including mining guru Barry FitzGerald - take you inside the copper and gold markets, and zero in on juniors exploring for the next major mine.
Biotron may be superhero for HIV patients
A drug which could make a huge difference to HIV-1 infected people has returned promising results – driving up biotech Biotron’s share price by 15 per cent.
Chariot gears up for summer lithium blitz at Black Mountain
Chariot Corporation has resumed hard rock lithium exploration at its Black Mountain project in Wyoming as the 2024 North American summer season kicks off.
US oil producer Brookside Energy’s profits set to gush: analyst
Research house MST Access has initiated coverage on Brookside Energy, one of the few ASX companies in the North American oil and gas sector with a valuation 5x its share price.
Five small caps tipped to hit new heights
Discovery Capital Partners says interest in the likes of gold, copper and graphite has risen, with small caps – such as these five – starting to see the love.